Emily Jones, MD
Family Medicine · Richardson, TXNPI 1235635996
Payments from drug & device makers
Across 423 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AbbVie$1K
- AstraZeneca$1K
- Bayer$876
- GSK$860
- Pfizer$589
- plus $5K from 30 others
What the payments were for
- Consulting fees$1,20011%
- Travel & lodging$3283%
- Food & beverage$9,34986%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $1,741 |
| AbbVie | 55 | $1,097 |
| AstraZeneca | 37 | $1,018 |
| Bayer | 24 | $876 |
| GSK | 32 | $860 |
| Pfizer | 27 | $589 |
| Astellas Pharma US Inc | 26 | $571 |
| Amgen | 32 | $462 |
| Otsuka America Pharmaceutical, Inc. | 22 | $390 |
| Lilly USA, LLC | 29 | $388 |
| Novo Nordisk | 21 | $370 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $313 |
| Idorsia Pharmaceuticals US Inc | 7 | $305 |
| Abbott | 10 | $272 |
| Sanofi-aventis U.S. LLC | 5 | $202 |
| Dynavax Technologies Corporation | 5 | $182 |
| Exact Sciences | 8 | $162 |
| Boehringer Ingelheim | 7 | $150 |
| Kowa Pharmaceuticals America, Inc. | 6 | $150 |
| Alnylam Pharmaceuticals Inc. | 5 | $111 |
| Genentech USA, Inc. | 5 | $104 |
| Novartis | 5 | $95 |
| Johnson & Johnson | 4 | $86 |
| Currax Pharmaceuticals LLC | 5 | $77 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Dexcom, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Cochlear Americas | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Amarin Pharma, Inc. | 2 | $32 |
| Almatica Pharma LLC | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Kerecis Limited | 1 | $16 |
| Athena Bioscience, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,901 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $116,734 |
| MounjaroTirzepatide | 98 | $108,024 |
| JardianceEmpagliflozin | 26 | $45,904 |
| FarxigaDapagliflozin Propanediol | 41 | $45,887 |
| MyrbetriqMirabegron | 29 | $31,537 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $24,515 |
| RybelsusSemaglutide | 15 | $23,401 |
| EliquisApixaban | 11 | $18,874 |
| Rosuvastatin Calcium | 355 | $3,327 |
| Atorvastatin Calcium | 285 | $2,936 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $2,787 |
| Lidocaine | 24 | $2,538 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $2,458 |
| Ramelteon | 19 | $2,390 |
| SynthroidLevothyroxine Sodium | 23 | $1,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $370 | $140,135124 claims |
| Lilly USA, LLCMounjaro | $388 | $108,02498 claims |
| Boehringer IngelheimJardiance | $150 | $45,90426 claims |
| AstraZenecaFarxiga | $1,018 | $45,88741 claims |
| Astellas Pharma US IncMyrbetriq | $571 | $31,53729 claims |
| GSKTrelegy Ellipta, Arexvy | $860 | $27,30234 claims |
| PfizerEliquis | $589 | $18,87411 claims |
| AbbVieSynthroid, Armour Thyroid | $1,097 | $2,64335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Richardson
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.